三星医疗
(601567)
| 流通市值：325.87亿 | | | 总市值：325.87亿 |
| 流通股本：14.05亿 | | | 总股本：14.05亿 |
| 报告期 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 11,079,882,357 | 7,972,213,807.13 | 3,630,793,866.31 | 14,600,478,206.12 |
| 营业收入 | 11,079,882,357 | 7,972,213,807.13 | 3,630,793,866.31 | 14,600,478,206.12 |
| 二、营业总成本 | 9,754,661,366.81 | 6,798,039,087.95 | 3,129,719,427.73 | 12,231,892,536.68 |
| 营业成本 | 7,926,582,593.22 | 5,662,487,680.53 | 2,581,339,583.91 | 9,530,646,989.31 |
| 税金及附加 | 76,918,164.24 | 47,603,899.45 | 16,343,496.31 | 94,914,144.68 |
| 销售费用 | 817,655,015.94 | 543,551,209.21 | 275,722,361.36 | 1,016,914,785.27 |
| 管理费用 | 620,195,598.45 | 402,411,172.52 | 185,589,270.36 | 907,462,644.87 |
| 研发费用 | 421,981,091.96 | 256,648,902.15 | 117,042,069.26 | 523,326,835.38 |
| 财务费用 | -108,671,097 | -114,663,775.91 | -46,317,353.47 | 158,627,137.17 |
| 其中:利息费用 | 88,168,433.04 | 61,242,021.8 | 33,387,710.86 | 95,000,557.44 |
| 其中:利息收入 | 29,062,779.53 | 21,652,341 | 10,267,105.72 | 75,791,055.47 |
| 三、其他经营收益 | | | | |
| 加:公允价值变动收益 | 153,378,976.8 | 25,303,376.96 | 71,839.66 | -172,769,034.39 |
| 加:投资收益 | 178,574,515.32 | 119,397,192.21 | 63,773,525.28 | 229,188,040.9 |
| 资产处置收益 | 532,653.11 | 1,035,852.35 | -270,075.28 | -35,698.18 |
| 资产减值损失(新) | -63,285,020.16 | -37,258,101.98 | -8,258,083.79 | -56,494,387.01 |
| 信用减值损失(新) | -35,220,622.1 | -26,338,566.13 | -28,873,380.73 | -31,489,568.08 |
| 其他收益 | 210,989,071 | 125,518,249.54 | 39,622,271.62 | 248,148,144.52 |
| 四、营业利润 | 1,770,190,564.16 | 1,381,832,722.13 | 567,140,535.34 | 2,585,133,167.2 |
| 加:营业外收入 | 34,020,864.08 | 29,073,683.63 | 3,746,360.96 | 122,232,451.98 |
| 减:营业外支出 | 24,184,118.74 | 9,680,871.31 | 2,295,040.12 | 34,808,996.58 |
| 五、利润总额 | 1,780,027,309.5 | 1,401,225,534.45 | 568,591,856.18 | 2,672,556,622.6 |
| 减:所得税费用 | 273,231,066.83 | 186,312,237.35 | 88,106,715.22 | 399,319,160.25 |
| 六、净利润 | 1,506,796,242.67 | 1,214,913,297.1 | 480,485,140.96 | 2,273,237,462.35 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | 1,506,796,242.67 | 1,214,913,297.1 | 480,485,140.96 | 2,273,237,462.35 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | 1,527,833,388.43 | 1,229,732,476.5 | 489,308,019.24 | 2,259,517,910.58 |
| 少数股东损益 | -21,037,145.76 | -14,819,179.4 | -8,822,878.28 | 13,719,551.77 |
| 扣除非经常损益后的净利润 | 1,279,539,454.95 | 1,135,714,146.5 | 460,138,324.11 | 2,201,698,748.71 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | 1.08 | 0.87 | 0.35 | 1.6 |
| (二)稀释每股收益 | 1.08 | 0.87 | 0.35 | 1.6 |
| 八、其他综合收益 | 520,929.54 | 44,675,974.27 | 14,203,090.27 | -3,372,669.3 |
| 归属于母公司股东的其他综合收益 | -1,003,923.92 | 40,369,432.21 | 15,267,346.55 | -2,000,312.76 |
| 九、综合收益总额 | 1,507,317,172.21 | 1,259,589,271.37 | 494,688,231.23 | 2,269,864,793.05 |
| 归属于母公司股东的综合收益总额 | 1,526,829,464.51 | 1,270,101,908.71 | 504,575,365.79 | 2,257,517,597.82 |
| 归属于少数股东的综合收益总额 | -19,512,292.3 | -10,512,637.34 | -9,887,134.56 | 12,347,195.23 |
| 公告日期 | 2025-10-30 | 2025-08-22 | 2025-04-25 | 2025-04-25 |
| 审计意见(境内) | | | | 标准无保留意见 |